NeflgArd: Nefecon Efficacy and Safety in IgAN Patients Completing the 2-Year Phase 3 Trial
In this medfyle
The gut mucosal immune system is implicated in the pathogenesis of IgAN, so an oral, targeted-release budesonide formulation has been designed to act at this site. In open-label extension data presented at Kidney Week 2024, a second 9-month course impacted proteinuria and kidney function, without additional safety concerns.
About this Medfyle
©2024 Infomedica-Medfyle. All rights reserved.
Source: NeflgArd Open-Label Extension: Efficacy and Safety of Nefecon in Patients with IgAN Who Completed the 2-Year Phase 3 Trial. Lafayette RA, et al. Presented at Kidney Week 2024; #FR-OR56.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
